SERENZA THERAPEUTICS LTD

Active London

Research and experimental development on biotechnology

Research and experimental development on biotechnology
S

SERENZA THERAPEUTICS LTD

Research and experimental development on biotechnology

Founded 11 Dec 2025 Active London, United Kingdom website.com
Research and experimental development on biotechnology
Accounts Due 11 Sept 2027 15 months remaining
Confirmation
Net assets N/A
Total assets N/A
Total Liabilities N/A
Charges None No charges registered

Contact & Details

Contact

Registered Address

71 Kingsway Holborn London WC2B 6ST United Kingdom

Full company profile for SERENZA THERAPEUTICS LTD (16904856), an active company based in London, United Kingdom. Incorporated 11 Dec 2025. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Awaiting first accounts
For period ending 31 December 2026
Due by 11 September 2027 15 months remaining

Financial History

Revenue, profit, EBITDA and key financial figures

No Financial Data Available

Financial information will appear here once available.

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

2 Allotments 11,090,000 Shares £1k Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
20 Jan 20265,000,000£500£0
24 Dec 20256,090,000$609$0

Officers

Officers

3 active
Status
Badamchi-zadeh, AlexanderDirectorBritishUnited Kingdom3811 Dec 2025Active
Dezfuly, Seyed Ali JazayeriDirectorBritishUnited Kingdom5020 Jan 2026Active
Foerch, Patrik, DrDirectorBritishUnited Kingdom5420 Jan 2026Active

Shareholders

Shareholders (1)

Sv Bco I Gp Llp (on Behalf Of Sv Biotech Crossover
100.0%
10,000

Persons with Significant Control

Persons with Significant Control (6)

6 Active 3 Ceased

Sv Bco I Gp Llp

Unknown

Active
Notified 11 Dec 2025
Nature of Control
  • Ownership Of Shares 75 To 100 Percent

Sv Health Managers Llp

Unknown

Active
Notified 11 Dec 2025
Nature of Control
  • Ownership Of Shares 75 To 100 Percent As Firm
  • Voting Rights 75 To 100 Percent
  • Voting Rights 75 To 100 Percent As Firm
  • Right To Appoint And Remove Directors
  • Right To Appoint And Remove Directors As Firm
Active
Notified 31 Dec 2025
Nature of Control
  • Ownership Of Shares 25 To 50 Percent As Firm
  • Voting Rights 25 To 50 Percent
  • Voting Rights 25 To 50 Percent As Firm
  • Right To Appoint And Remove Directors
  • Right To Appoint And Remove Directors As Firm

Nxera Pharma Uk Limited

Unknown

Active
Notified 20 Jan 2026
Nature of Control
  • Ownership Of Shares 25 To 50 Percent
  • Voting Rights 25 To 50 Percent
Active
Notified 31 Dec 2025
Nature of Control
  • Ownership Of Shares 25 To 50 Percent

Seyed Ali Jazayeri Dezfuly

British

Active
Notified 24 Dec 2025
Residence United Kingdom
DOB January 1976
Nature of Control
  • Ownership Of Shares 75 To 100 Percent
  • Voting Rights 75 To 100 Percent
  • Right To Appoint And Remove Directors

Seyed Ali Jazayeri Dezfuly

Ceased 31 Dec 2025

Ceased

Sv Health Managers Llp

Ceased 24 Dec 2025

Ceased

Sv Bco I Gp Llp

Ceased 24 Dec 2025

Ceased

Group Structure

Group Structure

SV HEALTH MANAGERS LLP united kingdom
SV BCO I GP LLP united kingdom
SERENZA THERAPEUTICS LTD Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
28 May 2026IncorporationMemorandum Articles
28 May 2026ResolutionResolutions
19 May 2026CapitalAllotment of shares (USD 1,110) on 11 May 2026
12 May 2026OfficersAppointment of Saoussen Ben Halima as director on 1 May 2026
6 May 2026Persons With Significant ControlCessation of Seyed Ali Jazayeri Dezfuly as a person with significant control on 31 Dec 2025
28 May 2026 Incorporation

Memorandum Articles

28 May 2026 Resolution

Resolutions

19 May 2026 Capital

Allotment of shares (USD 1,110) on 11 May 2026

12 May 2026 Officers

Appointment of Saoussen Ben Halima as director on 1 May 2026

6 May 2026 Persons With Significant Control

Cessation of Seyed Ali Jazayeri Dezfuly as a person with significant control on 31 Dec 2025

Recent Activity

Latest Activity

Memorandum Articles

5 days ago on 28 May 2026

Resolutions

5 days ago on 28 May 2026

Allotment of shares (USD 1,110) on 11 May 2026

2 weeks ago on 19 May 2026

Appointment of Saoussen Ben Halima as director on 1 May 2026

3 weeks ago on 12 May 2026

Cessation of Seyed Ali Jazayeri Dezfuly as a person with significant control on 31 Dec 2025

3 weeks ago on 6 May 2026